AndroGel (Testosterone Topical) Erythrocytosis Severity Grading Rubric

What Is Erythrocytosis and Why Does AndroGel Cause It?

Erythrocytosis refers to an absolute increase in red blood cell mass, clinically identified when hematocrit exceeds 52% in men. Testosterone stimulates erythropoiesis through two distinct mechanisms: direct stimulation of erythroid progenitor cells in bone marrow and suppression of hepcidin, which increases iron availability for hemoglobin synthesis [1]. These pathways operate regardless of whether testosterone is delivered by injection, patch, or gel.

AndroGel (testosterone 1% and 1.62% gel) delivers testosterone transdermally, producing steadier serum levels than intramuscular injections. This pharmacokinetic profile matters. Injectable testosterone cypionate creates supraphysiologic peaks in the 48-72 hours after injection, and these peaks drive stronger erythropoietic signaling. A 2017 pharmacokinetic comparison published in the Journal of Clinical Endocrinology & Metabolism demonstrated that transdermal testosterone maintained serum levels within the mid-normal range (400-700 ng/dL) with less peak-to-trough variation than biweekly intramuscular injections [2]. The clinical consequence: topical formulations produce erythrocytosis less frequently and at lower magnitude.

The FDA-approved prescribing information for AndroGel 1.62% reports hematocrit elevation above 54% in approximately 4.2% of treated patients during clinical trials, compared to 0.8% in placebo groups [3]. The incidence in real-world practice may be higher. A retrospective cohort analysis of 3,422 men on various testosterone formulations published in JAMA Internal Medicine found that 11.2% of men on any testosterone replacement developed hematocrit above 52% within the first year, though the rate was significantly lower for gel users (7.8%) than for injection users (15.4%) [4].

Risk factors compound the baseline drug effect. Men living at altitudes above 1,500 meters, those with obstructive sleep apnea, current smokers, and patients with chronic lung disease all carry higher baseline hematocrit. Starting TRT in these populations demands tighter surveillance.

The Three-Tier Severity Grading Rubric

No single professional society has published a formal numbered grading scale for testosterone-induced erythrocytosis. The rubric below synthesizes thresholds from the Endocrine Society 2018 Clinical Practice Guideline, the American Urological Association 2018 Testosterone Guideline, and the CTCAE v5.0 grading criteria for blood and lymphatic disorders [5][6][7].

Grade 1 (Mild): Hematocrit 52-54%

This range signals early erythropoietic response to testosterone. The patient remains below the viscosity threshold associated with thromboembolic events. Management: continue current AndroGel dose, recheck CBC in 4-6 weeks, counsel patient on hydration, and screen for modifiable risk factors (smoking, untreated sleep apnea). The Endocrine Society guideline states that hematocrit should be checked at baseline, 3-6 months after initiation, and then annually, but any value crossing 52% warrants accelerated follow-up [5].

Grade 2 (Moderate): Hematocrit 54-57%

This range carries measurable clinical risk. Blood viscosity increases exponentially above hematocrit 54%, and a large Swedish registry study (N=39,484) published in The BMJ found that men with hematocrit between 54% and 57% on testosterone had a hazard ratio of 1.6 (95% CI 1.2-2.1) for venous thromboembolism compared to men with hematocrit below 48% [8]. Management options at this grade include reducing the AndroGel dose (e.g., from 50.4 mg daily to 40.5 mg daily for the 1.62% formulation), switching to a lower-dose formulation, and performing therapeutic phlebotomy to acutely lower hematocrit. One unit of whole blood removal (approximately 450-500 mL) typically reduces hematocrit by 3 percentage points [9].

Grade 3 (Severe): Hematocrit >57%

This threshold mandates TRT discontinuation. The AUA guideline recommends withholding testosterone if hematocrit exceeds 54% and is explicit that values above this point require intervention [6]. At hematocrit above 57%, the risk of stroke, deep venous thrombosis, and pulmonary embolism rises steeply. Management: stop AndroGel immediately, perform therapeutic phlebotomy, recheck CBC weekly until hematocrit falls below 50%, investigate secondary causes (polycythemia vera, chronic hypoxia), and only consider re-initiating testosterone at a lower dose after normalization and shared decision-making with the patient.

Monitoring Protocol for Patients on AndroGel

The monitoring cadence should be tightest in the first year. Erythrocytosis development follows a predictable timeline: hematocrit begins rising within 2-4 weeks of TRT initiation, reaches a new steady state by 3-6 months, and plateaus thereafter in most men [10]. A prospective study of 120 hypogonadal men on testosterone gel published in Clinical Endocrinology found that the median time to peak hematocrit was 4.2 months, with 89% of erythrocytosis events detected by the 6-month blood draw [11].

The recommended schedule: draw a CBC before prescribing, then at 3 months, 6 months, 12 months, and annually. Any result showing hematocrit above 50% should trigger repeat testing in 4 weeks rather than waiting for the next scheduled draw. Document both the absolute hematocrit value and the change from baseline, because a man whose hematocrit jumps from 42% to 51% in 3 months is a different clinical situation than one who has been stable at 51% for two years.

Dehydration confounds results. A patient who gives a fasting, early-morning blood sample after overnight fluid restriction may show a hematocrit 2-3 points higher than a well-hydrated sample. Confirm any borderline elevation with a repeat draw under standardized conditions before making dose changes [12].

"We always confirm an elevated hematocrit with a second draw, ideally after ensuring the patient is well-hydrated, before adjusting testosterone therapy," stated the Endocrine Society guideline writing committee in their 2018 recommendations [5].

Topical vs. Injectable Testosterone: Erythrocytosis Risk Comparison

The difference is consistent across studies. Topical testosterone causes less erythrocytosis than injectable testosterone. A matter of pharmacokinetics. Intramuscular testosterone cypionate or enanthate (typically dosed every 1-2 weeks) creates supraphysiologic serum testosterone peaks of 1,000-1 to 500 ng/dL in the days after injection. These peaks strongly stimulate renal erythropoietin production. Gels maintain serum levels in the 400-700 ng/dL range with peak-to-trough variation of roughly 15-25%, far less erythropoietic stimulus [2].

A network meta-analysis of 15 randomized controlled trials (N=3,117) published in The Journal of Clinical Endocrinology & Metabolism in 2020 calculated the pooled incidence of hematocrit >54% as 3.4% for transdermal testosterone versus 9.8% for intramuscular testosterone (odds ratio 0.32 to 95% CI 0.18-0.56) [13]. The clinical implication is practical: for patients with baseline hematocrit above 48% or with risk factors for erythrocytosis, topical formulations like AndroGel represent a lower-risk choice.

Subcutaneous testosterone, dosed at smaller and more frequent intervals (e.g., 50-80 mg twice weekly), also appears to produce less erythrocytosis than traditional intramuscular dosing. A retrospective chart review of 207 men published in Translational Andrology and Urology found hematocrit elevation above 52% in 5.1% of subcutaneous users versus 14.8% of intramuscular users over 12 months [14].

Switching formulations is a valid management strategy. A man on intramuscular testosterone who develops Grade 2 erythrocytosis can be transitioned to AndroGel at an equivalent dose with a reasonable expectation that hematocrit will decrease by 2-4 percentage points over 8-12 weeks without requiring phlebotomy.

Therapeutic Phlebotomy: When, How, and How Often

Phlebotomy is the fastest intervention for elevated hematocrit. Each 450-500 mL unit of whole blood removed lowers hematocrit by approximately 3 percentage points within 24-48 hours [9]. The procedure is straightforward: it is identical to a blood donation and takes 15-20 minutes.

Indications for phlebotomy on AndroGel: any hematocrit above 54% that has been confirmed on a repeat draw, or any hematocrit above 57% on a single draw (treat as urgent). Target a post-phlebotomy hematocrit below 50%. For patients with hematocrit of 56%, a single unit removal will typically achieve this. For values above 58%, two sessions separated by 48-72 hours may be necessary.

Chronic reliance on phlebotomy signals a dosing problem. If a patient requires phlebotomy more than twice per year to maintain hematocrit below 54%, the testosterone dose is too high for that individual's erythropoietic sensitivity, and dose reduction should be prioritized [5].

Iron depletion is a real concern with repeated phlebotomy. Each unit of blood removes approximately 200-250 mg of elemental iron. After three to four phlebotomies, many patients develop iron-deficiency erythropoiesis, which can paradoxically cause microcytic anemia while the hematocrit remains artificially controlled. Monitor ferritin in patients undergoing repeated phlebotomy; values below 20 ng/mL indicate depleted stores [15].

"Therapeutic phlebotomy should be viewed as a bridge to dose optimization, not as a long-term management strategy for testosterone-induced erythrocytosis," according to guidance from the American Association of Clinical Endocrinology [16].

Long-Term Cardiovascular Implications of Erythrocytosis on TRT

The relationship between testosterone-induced erythrocytosis and cardiovascular events has been a contested area. Elevated hematocrit increases blood viscosity, which raises shear stress on vascular endothelium and promotes platelet aggregation. These are plausible mechanisms for increased thromboembolic risk. But separating erythrocytosis-mediated risk from other cardiovascular effects of testosterone has been difficult.

The TRAVERSE trial (Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response in Hypogonadal Men; N=5,204) published in the New England Journal of Medicine in 2023 found that testosterone replacement did not increase the composite rate of major adverse cardiovascular events (MACE) compared to placebo over a median follow-up of 33 months (HR 0.99 to 95% CI 0.81-1.21) [17]. This trial included men aged 45-80 with cardiovascular disease or high cardiovascular risk. Erythrocytosis (hematocrit >54%) occurred in 7.1% of testosterone-treated men versus 2.1% in the placebo group, but the trial was not powered to detect whether erythrocytosis specifically mediated thromboembolic events.

A post-hoc analysis of the TRAVERSE data presented at ENDO 2024 found that men who developed hematocrit above 54% had a numerically (but not statistically significantly) higher rate of venous thromboembolism (2.3% vs. 1.4%; p=0.09) [18]. The signal was suggestive but not definitive. Until larger, erythrocytosis-specific outcome data emerge, the prudent approach remains to treat hematocrit above 54% as a modifiable risk factor and intervene according to the severity grading rubric above.

The Swedish national registry study of testosterone-treated men (N=39,484) found that venous thromboembolism risk was concentrated in the first 6 months of therapy and in men with hematocrit above 54%, reinforcing the importance of early and frequent monitoring [8].

Dose Adjustment Strategies for AndroGel

AndroGel 1.62% is available in metered-dose pumps delivering 20.25 mg per actuation, with the usual starting dose at 40.5 mg (2 pumps) daily. The maximum approved dose is 81 mg (4 pumps) daily [3]. This granularity allows for precise titration.

For Grade 1 erythrocytosis (hematocrit 52-54%): maintain current dose, recheck in 4-6 weeks. If hematocrit continues rising, reduce by one pump actuation (20.25 mg).

For Grade 2 erythrocytosis (hematocrit 54-57%): reduce dose by 20.25-40.5 mg daily. If the patient is already on the minimum dose (20.25 mg daily) and hematocrit remains elevated, consider switching to a testosterone patch (which delivers even lower peak levels) or discontinuing TRT with a reassessment of the risk-benefit ratio.

For Grade 3 erythrocytosis (hematocrit >57%): stop AndroGel immediately. After hematocrit normalizes below 50% (typically 3-6 months), re-initiation may be considered at a 50% dose reduction from the prior regimen with CBC monitoring at 4, 8, and 12 weeks.

Every dose change should be paired with a serum total testosterone level drawn 2-4 hours after gel application (the approximate peak absorption window) to ensure the patient remains in the therapeutic range of 450-700 ng/dL. The goal is the lowest effective dose that resolves hypogonadal symptoms while keeping hematocrit below 52%.